Library
Proof of pharmacology of Org 48775-0, a p38 MAP kinase inhibitor, in healthy volunteers.
17 November 2020. doid: 10.1111/bcp.14655
Moerland M, Kales AJ, Broekhuizen K, Nässander U, Nelissen R, de Kam ML, Peeters PAM, Burggraaf J
View publicationTo investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the highly selective oral p38alpha/beta mitogen-activated protein (MAP) kinase inhibitor Org 48,775-0 in a first-in-human study.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
